University of Virginia Health System

• Fatty liver disease.  Our physicians are leaders in identifying factors that may cause nonalcoholic steatohepatitis (NASH). By partnering with leading biotechnology companies, we are developing antioxidants and novel therapies that may correct the underlying metabolic defects of this disease.

• Living Donor Transplantation. UVA is one of few sites in the U.S. to offer this novel and life-saving form of liver transplation, and was recently selected by the NIH as one of 10 U.S. centers to conduct a national study focused on the factors influencing outcomes of living donor liver transplants for both donors and recipients.  Carl Berg, M.D., Director of Hepatology, was selected to co-chair the national consortium.  "Knowledge obtained during the study will permit even better education of donors and transplant recipients about options related to liver transplantation," says Dr. Berg.  Our transplant team includes hepatologists, surgeons, pathologists, radiologists, nephrologists, pulmonologists and specialty nurse coordinators.  
  * To learn more click here. 
  * For the NIH news release on this study click here.

• Innovative use of immunosuppressants to treat chronic end-stage liver disease. Instrumental in developing advanced protocols resulting in better patient outcomes in controlling the response to hepatitis.

• Pegylated Interferon - antiviral agents. Improved post-transplant therapies to abate recurring hepatitis C infection.

Carl L. Berg, M.D.
Director of Hepatology and Liver Transplantation

Linda Romeo, RN, BSN

Patrick Northup, M.D.